Residual neurocognitive features of ecstasy use: A re-interpretation of halpern etal. (2011) consistent with serotonergic neurotoxicity

Addiction

Volumn 106, Issue 7, 2011, Pages 1365-1268

  Parrott, Andrew C ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Cognition; Ecstasy; Executive function; MDMA; Memory; Neurotoxicity; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; SEROTONIN RECEPTOR AFFECTING AGENT;

COGNITION; DRUG EFFECT; HUMAN; NEUROPSYCHOLOGICAL TEST; NOTE; PATHOPHYSIOLOGY; TOXICITY AND INTOXICATION;

COGNITION; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; NEUROTOXICITY SYNDROMES; SEROTONIN AGENTS;

EID: 79958004117     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2011.03437.x     Document Type: Letter

References (25)

1. Halpern J. H., Sherwood A. R., Hudson J. I., Gruber S., Kozin D., Pope H. G., Jr. Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs. Addiction 2011; 106: 777-86.
2. Rogers G., Elston J., Garside R., Roome C., Taylor R., Younger P. etal. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol Assess 2009; 13: 1-315.
3. Parrott A. C. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational Ecstasy users, the integrative role of bio-energetic stress. J Psychopharmacol 2006; 20: 147-63.
4. Topp L., Hando J., Dillon P., Roche A., Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 1999; 55: 105-15.
5. Parrott A. C. Chronic tolerance to recreational MDMA (3, 4 methylenedioxymethamphetamine) or ecstasy. J Psychopharmacol 2005; 19: 71-83.
6. Parrott A. C., Lock J., Conner A. C., Kissling C., Thome J. Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: prospective neuroendocrine and psychobiological changes. Neuropsychobiology 2008; 57: 165-80.
7. Fox H. C., McLean A., Turner J. J. D., Parrott A. C., Rogers R., Sahakian B. J. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ('ecstasy') polydrug users. Psychopharmacology 2002; 162: 203-14.
8. Parrott A. C. Cortisol and MDMA (3, 4-methylenedioxymethamphetamine): neurohormonal aspects of bioenergetic-stress in Ecstasy users. Neuropsychobiology 2009; 60: 148-58.
9. McCann U. D., Mertl M., Eligulasvili V., Ricaurte G. A. Cognitive performance in (+-) 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') uses: a controlled study. Psychopharmacology 1999; 143: 417-25.
10. Mc Cann U. D., Szabo Z., Vranesic M., Palermo M., Mathews W. B., Ravert H. T. etal. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3, 4-methylenedioxymethamphetamine ('ecstasy') users: relationship to cognitive performance. Psychopharmacology 2008; 200: 439-50.
11. Rodgers J. Cognitive performance amongst recreational users of 'ecstasy'. Psychopharmacology 2000; 151: 19-24.
12. Quednow B. B., Jessen F., Kuhn K. U., Maier W., Daum I., Wagner M. Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction. J Psychopharmacol 2006; 20: 373-84.
13. Kish S. J., Lerch J., Furukawa Y., Tong J., McCluskey T., Wilkins D. etal. Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain 2010; 133: 1779-97.
14. Wareing M., Fisk M., Murphy J. E. Working deficits in current and& previous users of MDMA ('ecstasy'). Br J Psychol 2000; 91: 181-8.
15. Montgomery C., Hatton N. P., Fisk J. E., Ogden R. S., Jansari A. Assessing the functional significance of ecstasy related memory deficits using a virtual reality paradigm. Hum Psychopharmacol 2010; 25: 318-25.
16. Rendell P. G., Gray T. J., Henry J. D., Tolan A. Prospective memory impairment in 'ecstasy' (MDMA) users. Psychopharmacology 2007; 194: 497-504.
17. Morgan M. J. Memory deficits associated with recreational use of 'ecstasy' (MDMA). Psychopharmacology 1999; 141: 30-6.
18. Zakzanis K. K., Campbell Z. Memory impairment in now abstinent MDMA users and continued users: a longitudinal follow-up. Neurology 2006; 66: 740-1.
19. Reay J. L., Hamilton C., Kennedy D. O., Scholey A. B. MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes. J Psychopharmacol 2006; 20: 385-8.
20. Fisk J. E., Montgomery C., Wareing M., Murphy P. N. Reasoning deficits in ecstasy (MDMA) polydrug users. Psychopharmacology 2005; 181: 550-9.
21. Halpern J. H., Pope H. G., Sherwood A. R., Barry S., Hudson J. I., Yurgelun-Todd D. Residual effects of illicit 3, 4-methylenedioxymethamphetamine in individuals with minimal exposure to other drugs. Drug Alcohol Depend 2004; 75: 135-47.
22. Morgan M. J. Recreational use of 'ecstasy' (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 1998; 19: 252-64.
23. Cowan R. L. Neuroimaging research in human MDMA users: a review. Psychopharmacology 2007; 189: 539-6.
24. Jacobsen L. K., Mencl W. E., Pugh K. R., Skudlarski P., Krystal J. H. Preliminary evidence of hippocampal dysfunction in adolescent MDMA ('ecstasy') users: possible relationship to neurotoxic effects. Psychopharmacology 2004; 173: 383-90.
25. Burgess A. P., Venables L., Jones H., Edwards R., Parrott A. C. Evidence for selective impairments of verbal recollection in abstinent recreational users of methylenedioxymethamphetamine ('ecstasy'). Psychopharmacology 2011. Epub ahead of print 10 March.